NEW YORK, Jan. 13, 2017 /PRNewswire/ -- Lawsuits filed on behalf of cancer patients who allegedly experienced permanent hair loss due to treatment with Taxotere continue to move forward in the federal multidistrict litigation now underway in the U.S. District Court, Eastern District of Louisiana. Several new Pretrial Orders have been issued in the proceeding, including an Order dated January 9, 2017 that extended the deadline for the submission of a Common Benefit Order until January 13th. An Order dated January 11, 2017 clarifies that the scope of the litigation is to include claims that cite generic versions of Taxotere, as well as lawsuits involving the name-brand medication. A second Order issued the same day directs the parties to submit proposed Plaintiff Facts Sheets and Defendant Fact Sheets by January 23rd. (In Re: Taxotere (Docetaxal) Products Liability Litigation - MDL No. 2740)
"Our Firm continues to evaluate Taxotere lawsuits involving permanent alopecia, and we are pleased that the federal litigation is moving forward. We will continue to monitor the proceeding for any developments that have the potential to impact our clients' claims," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs. The Firm is now offering free case reviews to breast cancer patients and others who experienced permanent hair loss allegedly associated with Taxotere cancer treatment.
Court documents indicate that more than 260 Taxotere lawsuits are now pending in the Eastern District of Louisiana, where all federally-filed product liability claims involving the chemotherapy agent's alleged association with permanent hair loss have been centralized for coordinated pretrial proceedings. While alopecia is a common side effect of chemotherapy, plaintiffs claim that Taxotere hair loss is more likely to be permanent compared to alopecia that occurs with equally effective, alternative drugs. By the late 1990s, Sanofi-Aventis and other defendants were purportedly aware of research suggesting that 9.2 percent of Taxotere patients experienced persistent alopecia for up to 10 years or longer. In 2006, a Denver-based oncologist had observed that an increased percentage of his Taxotere patients suffered from permanent hair loss for years after discontinuing the drug. Yet, in the U.S., patients and doctors were only provided with a "generic, vague and insufficient" warning that "hair generally grows back."
Taxotere was approved by the U.S. Food & Drug Administration in 1996 to treat breast cancer. The drug is now indicated to treat other malignancies, including head and neck cancer, gastric cancer, prostate cancer and non-small cell lung cancer. However, it wasn't until December 2015 that any information regarding reports of permanent alopecia was included on the labeling provided to doctors and patients in this U.S.
Taxotere cancer patients who experienced persistent, permanent alopecia following chemotherapy with this medication may be entitled to compensation. To learn more about filing a Taxotere lawsuit, please visit Bernstein Liebhard LLP's website, or call 800-511-5092 to arrange for a free, no obligation case review.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal's "Plaintiffs' Hot List," recognizing the top plaintiffs firms in the country. This year's nomination marks the thirteenth year the firm has been named to this prestigious annual list.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2017 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
SOURCE Bernstein Liebhard LLP